BRAF and non-small cell lung carcinoma: Based on the knowledge of genomic alterations, targeted therapy becomes the first‐line treatment for selected NSCLC patients, including inhibitors for EGFR, ALK, ROS1, BRAF, NTRK1/2/3, MET, and RET (Table 1).